BOEHRINGER-INGELHEIM
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Successfully Placed an Inaugural EUR 500 Million Single Tranche Eurobond and New Dual Tranche CHF 435 Million CHF Bonds14.3.2025 07:00:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma (SIX: GALD) has made significant progress on its refinancing strategy to spread out its maturity profile, diversify funding sources and reduce its interest costs, by successfully issuing the following bonds: EUR 500 million bond, with a 5-year maturity and a 3.5% fixed-rate annual coupon CHF 190 million bond, with a 4-year maturity and a 1.4025% fixed-rate annual coupon CHF 245 million bond, with a 8-year maturity and a 1.8098% fixed-rate annual coupon The payment dates are March 20, 2025, for the Eurobond and the CHF bonds. The bonds will be listed on the SIX Swiss Exchange. The EUR transaction was led by BNP Paribas, J.P. Morgan, Mizuho, and Santander as active bookrunners, while the CHF transaction was led by UBS and BNP Paribas. Galderma is rated BBB (stable outlook) by Fitch and Fitch is expect
Cessna Citation X and X+ Customers Benefit From Starlink High-Speed Internet Availability13.3.2025 16:00:00 CET | Press release
Textron Aviation today announced an additional high-speed internet connectivity solution for the Cessna Citation X and X+ following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313683324/en/ Textron Aviation announced an additional high-speed internet connectivity solution for the Cessna Citation X and X+ following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. (Photo Credit: Textron Aviation) Beechcraft, Cessna and Hawker customers receive factory-direct suppor
ClickHouse Acquires HyperDX to Accelerate the Future of Observability13.3.2025 16:00:00 CET | Press release
ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. This strategic acquisition reinforces ClickHouse's commitment to delivering the fastest, most cost-effective, and scalable solutions to developers and enterprises worldwide; including observability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313954782/en/ ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. (Graphic: Business Wire) The acquisition combines ClickHouse's unmatched performance and scalability with HyperDX's developer-first experience, creating a comprehensive observability platform that seamlessly integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing through an OpenTelemetry
Credit Derivatives Determinations Committees Membership Applications for 202513.3.2025 15:33:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Wednesday, March 19, 2025. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-co
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202413.3.2025 15:17:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,295.9 million (€2,118.0 million in 2023);EBITDA at €410.6 million (€352.1 million in 2023);EBIT at €330.4 million (€292.7 million in 2023)Group net profit at €211.1 million (€186.7 million in 2023)Approval of the proposed dividend distribution of €1.15 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2024, which will be submitted for approval to the Shareholders’ Meeting to be held in a single call in Turin on 23 April 2025. The Reply Group closed 2024 with a consolidated turnover of €2,295.9 million an increase of 8.4% compared to €2,118.0 million in 2023. All indicators are positive for the period. Consolidated EBITDA was €410.6 million, an increase of 16.6% compared to €352.1 million at December 2023. EBIT, from January to December, was at €330.4 million, which is an increase of 12.9% compared to €292.7 million at December 2023. The Group net p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom